| |
|
|
|
CfPA- The Center for Professional Advancement, Amsterdam, The Netherlands
2-5 June, 2020
Who Should Attend?
This broadly based course is intended for all scientists and technologists concerned with the development and processing of tablets, capsules and similar products, and with related drug regulatory affairs.
The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
• Quality Assurance
• Marketing
• Validation
• Purchasing
• R&D
• Regulatory Affairs
• Manufacturing/Production
• Engineering Support
Note: Persons seeking an in-depth treatment of only one or two of the major topics of this broadly based program may wish to consider alternative, more specialized courses offered by CfPA in this area of technology. Course Description
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA- The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
 Dr. Cecil W. Propst, Managing Director, Propst Consulting Services |
Dr. Cecil W. Propst is Managing Director at Propst Consulting Services, a formulation, and engineering support LLC located in Norton Shores MI. He was Director of R&D at SPI Pharma until 2015 where he developed and transferred products in extrusion, high shear, fluid beds and spray drying processes. He served as Director of Quality Assurance and Technical Services at Fleming and Company, previously, President of Manufacturing Chemists. Dr. Propst’s experience at Glaxo was in the area of process and product development and design optimization with applications in both batch and continuous processing. While at Stellar, as Director of Technical Development, his focus was on development, installation and validation of a continuous direct compression process. Dr. Propst developed and scaled up eight generic drug products during his tenure at the University of Maryland as part of the SUPAC Project,. Also, as part of the SUPAC Project, which was sponsored by the US FDA, Dr. Propst assisted in the development of ANDA data submission entry screens, the SUPAC similar equipment manual and conducted monthly training sessions of US FDA NDA/OGD reviewers in various areas of processing and formulation development to aide in the drug submission reviewing process.
Dr. Propst has published numerous articles and chapters in areas of design characterization, mixing, granulating, drying and tableting of powders. Dr. Propst holds five patents and currently has three additional product design patents pending. Dr. Propst currently serves as a consultant in the area of product development and process investigations for the chemical, diagnostic, food, engineering and beverage industries.
Additional Faculty
Jorg Cronlein, Senior Area Technical Manager, Colorcon
Ms Jane Fraser, Site Lead, Lonza, Edinburg
Mr. Dilip Parikh, President and CEO, DPharma Group
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
knee@cfpa.com
|
|
|
|
|
|
|
|
|
Formal sessions of the course are supplemented with informal discussion periods between lecturers and course participants and problem-solving sessions are held on both an open and private basis.